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ABSTRACT. How anti-Alzheimer's drug candidates that reduce amyloid 1-42 peptide 
fibrillization interact with the most neurotoxic species is far from being understood. We report 
herein the capacity of sugar-based peptidomimetics to inhibit both Aβ1-42 early oligomerization 
and fibrillization. A wide range of bio- and physico-chemical techniques, such as a new capillary 
electrophoresis method, nuclear magnetic resonance, and surface plasmon resonance, were used 
to identify how these new molecules can delay the aggregation of Aβ1-42. We demonstrate that 
these molecules interact with soluble oligomers in order to maintain the presence of non-toxic 
monomers and to prevent fibrillization. These compounds totally suppress the toxicity of Aβ1-42 
towards SH-SY5Y neuroblastoma cells, even at sub-stoichiometric concentrations. Furthermore, 
demonstration that the best molecule combines hydrophobic moieties, hydrogen bond donors and 
acceptors, ammonium groups and a hydrophilic β-sheet breaker element, provides valuable 
insight for the future structure-based design of inhibitors of Aβ1-42 aggregation. 
 
INTRODUCTION 
Protein-protein interactions mediating protein aggregation concern at least 30 different proteins 
and are associated with more than 20 serious human diseases, including Alzheimer’s (AD), 
Parkinson’s disease and type 2 diabetes mellitus. The accumulation of extra- or intracellular 
Page 2 of 58
ACS Paragon Plus Environment





























































 protein deposits, often referred to as amyloid, characterize these protein misfolding diseases. AD, 
which is the most common form of late-life dementia,
1 
is associated with accumulation of 
intraneuronal neurofibrillary tangles and extracellular ‘senile’ plaques containing insoluble 
fibrils composed of 40 or 42-residue amyloid-β peptides (Aβ1-40 or Aβ1-42).
2
 Monomeric Aβ 
peptides convert into fibrils
 
through a complex nucleation process involving the formation of 
various aggregated species such as soluble oligomers and protofibrils of increasing size.
3-5 
Structural studies have reported that oligomeric and fibrillar species share a β-sheet rich 
conformation,
6-10
 however the structure of the different oligomeric species is far from being 
understood. Although Aβ1-42 is not the most abundant amyloid peptide produced in vivo, it is the 
major constituent of amyloid plaques and is far more aggregative and neurotoxic than Aβ1-40.
11,12
 
Experimental evidence supports the hypothesis that low molecular weight oligomers are 
primarily responsible for the neurodegeneration observed in AD.
2,11,13-16
 However, the role of 
fibrils should not be neglected, because they have been demonstrated not to be inert species, but 
are able to generate damaging redox activity and promote the nucleation of toxic oligomers.
17,18
 
Hence it remains crucial to develop inhibitors that can reduce the prevalence of small transient 
oligomers and also prevent the formation of fibrils. Numerous compounds have been reported as 
inhibitors or modulators of Aβ1-42 aggregation. The main drawbacks of the described molecules 
that jeopardize their development as drug candidates are: a lack of binding selectivity leading to 
a high risk for various side-effects for dyes or polyphenol natural products
19
; poor bioavailability 
and high propensity to self-aggregate for peptide derivatives
20,21
; and a general lack of 
information regarding their mechanism of action, and in particular on their effects on toxic 
oligomers formation.
19-21
 To our knowledge, rationally designed small and ‘druggable’ pseudo- 
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 or non-peptidic aggregation inhibitors have been very scarcely reported.
22,23
 Some of us have 
described retro-inverso peptide inhibitors of both early oligomerization and fibrillization.
22
 
We previously reported a novel class of glycopeptide derivatives, based on two hydrophobic 
dipeptides (Ala-Val and Val-Leu) linked to a hydrophilic D-glucopyranosyl scaffold through 
aminoalkyl and carboxyethyl linkers in C1 and C6 positions, respectively (compound 1, Figure 
1).
24
 These pentapeptide analogs were shown to modulate Aβ1-40 and Aβ1-42 aggregation, as 
demonstrated by fluorescence Thioflavin-T (ThT) assays and transmission electron microscopy 
(TEM).
24
 The flexible and hydrophilic sugar moiety is believed to act as a β-sheet breaker, 
playing a major role in preventing the interactions between Aβ species and thus inhibiting the 
aggregation. The introduction of a carbohydrate in peptides can also have a multifaceted impact 
on the properties of these molecules, such as modulating the hydrophilicity/hydrophobicity 
balance and conferring resistance to proteolytic cleavage.
25
 
In order to further decrease the number of potential sites for proteolytic attack, we have now 
introduced peptidomimetics in the upper arm in the C6 position. A wide range of bio- and 
physico-chemical techniques was then used in order to evaluate the activity of the synthesized 
small hydrosoluble peptidomimetic compounds on the early oligomerization, fibrillization and 




As we have already demonstrated the superiority of the β configuration of the C1 anomeric 
carbon in our previously reported glycopeptides,
24b
 we decided in a first attempt to evaluate the 
mixture of α and β anomers, to avoid a difficult separation of the two anomers. Furthermore, as 
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 we have also clearly demonstrated the superiority of the amino propyloxy link relative to the 
amino ethyloxy link, in the C1 position of the sugar moiety,
24b
 we decided to prepare 
glycopeptidomimetics bearing the amino propyloxy link. For the design of the peptidomimetic 
strands, we chose to replace the C-terminal leucine (Leu5 in compound 1, Figure 1) by the 5-
amino-2-methoxybenzhydrazide unit (compounds 2 and 3, Figure 1), which is a part of the β-
strand mimic (“Hao” unit) reported by Nowick and co-workers.
21,26 
The introduction of a 5-
amino-2-methoxybenzhydrazide unit into β-strand mimics was shown, by some of us, to be 
extremely effective in the prevention of protein-protein interactions involving intermolecular β-
sheets of HIV-1 protease in order to inhibit its dimerization, while increasing the proteolytic 
stability of the molecules.
27
 In a first generation, the valine residue (Val4 in compound 1, Figure 
1) was kept and linked to the 5-amino-2-methoxybenzhydrazide unit (compound 2, Figure 1). 
Next, the valine residue was replaced by a lysine residue, to further provide these molecules with 
the possibility of engaging in electrostatic interactions with Aβ1-42, in order to increase their 
affinity for Aβ1-42 (compound 3, Figure 1). 
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2  C1= α,β

















































Figure 1. Structure of glycopeptidomimetic derivatives 1-3 
Synthesis of the glycopeptidomimetics  
A short and robust synthesis of the intermediate 9 was developed (Scheme 1A). We started 
from the C1 allylic protected D-glucose which was transformed into 4 following the procedure 
described in the literature.
28
 The Michael addition of 4 on tert-butylacrylate was performed to 
give 5. The allyl group of 5 was then removed from the C1 hydroxyl group with PdCl2 to give 
compound 6 in good yield. The anomeric hydroxyl of 6 was converted into the 
trichloroacetimidate intermediate 7, in the presence of trichloroacetonitrile and using NaH as a 
base. The nucleophilic substitution reaction by 3-azidopropan-1-ol was then carried out in the 
presence of AuCl (10%) affording 8 in good yield. The α and β epimers 8 were obtained in equal 
proportion and could not be separated at this stage. The tert-butyl group was finally cleaved in 
acidic conditions to give the carboxylic acid 9. 
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 The scaffold 9 was then coupled with the peptidomimetic arms 10 and 11 prepared according to 
our published procedure
27
, using DMTMM ([4-(4,6-Dimethoxy1,3,5-triazin-2-yl)-4-methyl-
morpholinium tetrafluoroborate])
29
 as coupling agent (Scheme 1B). Compounds 12 and 13 were 
obtained in good yield. The azido group of 12 and 13 was then reduced via a Staudinger 
reaction
30 
to give the corresponding amines, 14 and 15 in satisfactory yields. In order to build the 
peptidic arm in C1, the two amino acids N-Boc-L-Val-OH and N-Boc-L-Ala-OH were 
successively coupled by a standard coupling/deprotection protocol to afford 18 and 19 from 14 
and 15 respectively, in good yields. Hydrogenolysis of 18 and 19 afforded 20 and 21, which 
underwent an acidic cleavage of the tert-butyl carbamate to give 2 and 3. The acidic cleavage of 
the tert-butyl carbamate was also performed on benzylated compounds 18 and 19 to afford 22 
and 23. All the desired compounds were obtained as a mixture of α and β anomers. The β anomer 
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10 R = CH(CH3)2
11 R = (CH2)4NHCbz
12 R = CH(CH3)2
13 R = (CH2)4NHCbz
14  R = CH(CH3)2


























16 R = CH(CH3)2
17 R = (CH2)4NHCbz
18    R = CH(CH3)2
















































20   R = CH(CH3)2  



























































22  R = CH(CH3)2  
23  R = (CH2)4NHCbz
g
 
Scheme 1. Synthesis of glycopeptidomimetics. A- Synthesis of the scaffold 9. Reagents and 
conditions: a) tert-butyl acrylate, TBAB, 20% NaOH aq., rt, 24h, 79%; b) PdCl2, CH3OH/EtOH, 
N2 atm. rt, overnight 75% ; c) CCl3CN, NaH, CH2Cl2, rt, overnight, 75%; d) 3-azidopropan-1-ol, 
AuCl (10% w/w), CH2Cl2, N2 atm., rt, 2 days, 82%; e) TFA, CH2Cl2, rt, overnight, 72%. B- 
Synthesis of glycopeptidomimetics 2 and 3. Reagents and conditions: a) NMM, DMTMM, DMF, 
rt, overnight, 86% (12), 68%, (13); b) Ph3P, THF/H2O (9:1), 40 °C, 24h, 63% (14), 50% (15); c) 
N-Boc-L-Val-OH, NMM, DMTMM, DMF, rt, overnight, 79% (16), 68% (17); d) TFA, CH2Cl2, 
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 rt, 3h, quantitative; e) N-Boc-L-Ala-OH, NMM, DMTMM, rt, overnight, 68% (18), 73% (19); f) 
H2 Pd/C, rt, MeOH, 48h, 88% (20); 75% (21); g) TFA, CH2Cl2, rt, 3h, quantitative. 
Inhibition of Aβ1-42 fibrillization by glycopeptidomimetics  
ThT-fluorescence assays 
The ability of compounds 1-3 and of intermediates 19-23 to inhibit the fibrillization of Aβ1-42 
was studied by ThT fluorescence spectroscopy.
31 
The fluorescence curve for Aβ1-42 at a 
concentration of 10 µM followed the typical sigmoidal pattern with a lag phase of 8–9 h 
followed by an elongation phase and a final plateau reached after 17-18 h (purple curve, Figure 
2A). Two parameters were derived from the ThT curves of Aβ1-42 alone and Aβ1-42 in the 
presence of the evaluated compound: (1) t1/2, which is defined as the time at which the half 
maximal ThT fluorescence is observed and gives insight on the rate of the aggregation process; 
(2) F, the fluorescence intensity at the plateau which is assumed to be dependent on the amount 
of fibrillar material formed (Table 1, Figures 2A-C).  
The glycopeptidomimetic molecules 2 and 3 were dramatically more efficient inhibitors of 
Aβ1-42 aggregation than the glycopeptide compound 1 in particular at lower compound/ Aβ1-42 
ratios of 1/1 and even 0.1/1. It is noteworthy that a lysine residue attached to the 5-amino-2-
methoxybenzhydrazide unit was highly beneficial for the activity compared to a valine residue 
(compare 3 vs 2 and 21 vs 20). The free amine of the lysine residue side chain is thus beneficial 
for the activity. However, no dramatic effect of the N-terminal free amine of the dipeptide Val-
Ala chain was observed in both lysine and valine series. Indeed, a similar activity was obtained 
for the free amine 3 and the Boc protected 21 from one hand and for the free amine 2 and the 
Boc protected 20 on the other hand. It was also remarkable that the β anomer 3β showed a 
superior activity to the mixture of α and β anomers in 3 at low compound/Aβ1-42 ratios (1/1 and 
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 0.1/1, Table 1 and Figures 2A-C). A supplementary ThT fluorescence assay was performed by 
first, adding compound 3 after 4 hours, when presumably oligomers are already formed and 
secondly, adding compound 3 after 42 hours, when presumably essentially fibrils are present 
(Figure 1S in supporting information). A similar activity was obtained with compound 3 added at 
the beginning of the kinetics or after 4 hours. However no effect (or even a slightly increase of 
fluorescence) was observed when compound 3 was added after 42 hours. As also observed in our 
previous glycopeptides series,
24b
 benzylated derivatives 19, and 22-23 tended to self-aggregate 
and to slightly accelerate the aggregation process (Table 3S and Figure 1S in supporting 





Table 1. Effects of compounds 1, 2, 3, 3β, 20 and 21 on Aβ1-42 fibrillization assessed by ThT-
fluorescence spectroscopy at a compound/Aβ1-42 ratio of 10/1 and 1/1 (the concentration of Aβ1-












1 10/1  280±70 –56±9  
1 1/1 ne ne 
   
2 10/1 325 ± 12 –31±7 
2 1/1 155± 10 ne 
   
3 10/1 NA –87±1 
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 3 1/1 148±12 –29±9 
3 0.1/1 ne –23±6 
   






 3β 0.1/1 129±12 –16±6 
   
20 10/1 379±15 –41±22 
20 1/1 138±10 ne 
   
21 10/1 NA –84±3 
21 1/1 154±8 ‒26±6 
   
ne = no effect, NA = no aggregation, parameters are expressed as mean ± SE, n=3-6. [a] See 
supporting information for the calculation of the t1/2 increase. A compound displaying a t1/2 
increase > 100 % is a delayer of aggregation. [b] See supporting information for the calculation 
of the plateau decrease.  
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Figure 2. Effects of derivatives 3 and 3β on the fibrillization kinetics of Aβ1-42 monitored by 
Thioflavin-T fluorescence and TEM. A) Representative curves of ThT fluorescence assays over 
time showing Aβ1-42 (10 µM) aggregation in the absence (purple curve) and in the presence of 
compounds 3 (blue curves) and 3β (red curves) at compound/Aβ1-42 ratios of 10/1, 1/1 and 0.1/1. 
B) t1/2 increase relative to Aβ1-42 alone, in the presence of compounds 3 (blue curves) and 3β (red 
curves) at compound/Aβ1-42 ratios of 10/1 and 1/1. C) Fluorescence plateau decrease relative to 
Aβ1-42 alone, in the presence of compounds 3 (blue curves) and 3β (red curves). D) Effects of 
derivative 3 on the fibril formation of Aβ1-42 visualized by TEM. Negatively stained images were 
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 recorded after 42 h of incubation of Aβ1-42 (10 µM in 10 mM Tris.HCl, 100 mM NaCl at pH = 
7.4) alone (left) or in the presence of 10 µM of 3 (middle) and of 100 µM of 3 (right). Scale bars, 
500 nm. 
TEM experiments 
Transmission electron microscopy (TEM) analyses were performed on compound 3 that 
showed a more significant effect than 2 on Aβ1-42 aggregation in the ThT-fluorescence assays. 
Images were recorded after 42 h of preincubation, corresponding to maximum aggregation in the 
ThT assays, with and without 3 (Figure 2D). Differences were observed regarding the amount of 
aggregates formed in the presence of 3 at both ratios. A very dense network of fibers displaying a 
typical morphology was observed for Aβ1-42 alone. Only few scattered, very short and scarce 
fibers were visible on the grid containing the Aβ sample incubated with 3 at 10/1 ratio. This 
result validated the ThT-fluorescence data, indicating that compound 3 dramatically slowed 
down the aggregation of Aβ1-42 (at 3/Aβ1-42 ratio of 10/1) and efficiently reduced the amount of 
typical amyloid fibrils formed. It is noteworthy that even if at a 3/Aβ1-42 ratio of 1/1 the 
fluorescence was not dramatically decreased in the ThT assays, but the morphology of the 
network observed by TEM was very different and less dense and the sample contained some 
globular aggregates.  
 
Inhibition of Aβ1-42 oligomerization by glycopeptidomimetics 
Capillary electrophoresis 
In order to determine their effect on small soluble oligomer formation, 3 and 3β were studied 
by Capillary Electrophoresis (CE). We recently proposed an improved CE method to monitor 
easily over time the very early steps of the Aβ1-42 oligomerization process.
32,24b  
This technique 
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 has the advantage of being able to follow three kinds of soluble species, (i) the monomer (peak 
ES), (ii) different small metastable oligomers grouped under peak ES’ and (iii) transient species 
formed later and which correspond to species larger than dodecamers (peak LS). Aggregation 
kinetics of Aβ1-42 alone showed that over time, the monomer ES peak decreased in favor of the 
oligomer peaks ES’ and LS, and of insoluble species, forming spikes in the profile (Figure 2S in 
supporting information for the detailed kinetics). At time 0, the monomer peak ES was almost 
the only visible species, while after 12 h, only a small monomer peak remained and many 
insoluble aggregates, giving spikes, were present (Figure 3A).  
In the presence of 3β (3β /Aβ1-42 ratio of 1/1), the electrophoretic profile clearly indicated that 
the kinetics of aggregation was significantly slowed down. Indeed, 3β maintained dramatically 
the presence of the monomer (peak ES). In addition, the large oligomer species grouped under 
the peak LS were still present at 12 h while they completely disappeared in the control 
electrophoretic profile (Figure 3B, and Figure 3S in supporting information for the detailed 
kinetics). The preservation of the monomer was statistically significant, after 12 h, only 19% 
remained in the control experiment while 52% remained in the presence of 3β (Figure 3C). 
Similar results were observed with the mixture of α and β anomers in 3, however a slightly 
superior effect was observed for 3β (41% of monomer species remained after 12 h in the 
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Figure 3. Effect of 3β on the early oligomerization steps by CE. Electrophoretic profile of Aβ1-42 
peptide (100 µM) obtained immediately (0 h), and 12 h after sample reconstitution (t0) alone (A) 
and in the presence of compound 3β at compound/Aβ1-42 ratio of 1/1 (B). Results in panel show 
the effect of 3β on the monomer ES (C). Results are a mean of 3 experiments. 
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 The goal of the NMR experiments was to study if compound 3β was able to adopt any 
preferred conformation in solution and if it interacted in solution either with the monomeric 
species or with soluble aggregated forms of Aβ1-42. 
We first examined mixtures of Aβ1-42 and 3β at a temperature of 5°C and using low 
concentrations of Aβ1-42 (10–90 µM) to ensure that Aβ1-42 was mainly monomeric in freshly 
prepared samples.
33















recorded in the absence and in the presence of a large excess of 3β (0.4 mM) displayed 








C correlations (Figure 6S in 
supporting information). Similarly, no chemical shift differences could be detected for the 
1
H 
signals of 3β in 1D 
1




H experiments (data not shown), even when higher 
concentrations of Aβ1-42 were used (up to 90 µM). Thus NMR experiments demonstrated that 3β 
did not interact with monomeric Aβ1-42 peptide. 
We then turned to magnetization transfer experiments that are commonly used to detect the 
binding of small ligands to large molecular weight species. Saturation Transfer Difference (STD) 
experiments were recorded to characterize binding properties and map binding epitopes of 3β.
24a, 
35
 No STD signals could be detected in a control experiment with 3β alone, as expected for a low 
molecular weight molecule that did not aggregate in solution. The addition of Aβ1-42 peptide led 
to the apparition of weak STD signals (Figure 4). Interestingly, an increase in the STD signal 
was observed over time, reaching a maximum after 2.5 weeks. Concomitantly, a slow decay of 
the 1D 
1
H NMR signals of Aβ1-42 was observed (Figure 7S in supporting information), 
corresponding to the formation of high molecular weight Aβ1-42 aggregates that were too large to 
be observed by solution NMR spectroscopy.
33
 Thus the gradual increase of the STD signal over 
several weeks could be explained by the slow conversion of monomeric Aβ1-42 to aggregated 
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 species that bind 3β. The STD signals were the strongest for the aromatic and methyl resonances 
of 3β, suggesting that the hydrophobic groups of the dipeptide and peptidomimetic strands were 
directly involved in the interaction with Aβ1-42 species.  
WaterLOGSY experiments also enabled us to detect the binding of 3β to Aβ1-42 species, 
through intermolecular magnetization transfers involving bulk water. The protons of 3β 
exhibited positive NOEs in the absence of Aβ1-42 (Figure 8S in supporting information), as 
expected for a small molecule. The addition of Aβ1-42 caused a decrease of positive NOEs and a 
change of sign of the NOEs that became more negative over time, confirming that 3β binds to 
high molecular weight species in fast exchange on the NMR time scale. 
Finally, NMR spectroscopy was used to analyze the structure of 3β in the free and bound 
forms. The 1D 
1
H NMR spectra of 3β alone were characterized by sharp line widths and 
concentration-independent chemical shifts (0.04–2 mM range), demonstrating that 3β was highly 
soluble and not prone to aggregation in the (sub) millimolar range. Chemical shifts, vicinal 
coupling constants and ROEs analysis showed that the peptidic/pseudopeptidic arms and the 
aminoalkyl and carboxyethyl linkers were highly flexible, as supported by small diastereotopic 
splitting of methylenic protons, averaged vicinal coupling constants (Table S1 in supporting 
information), intraresidual and sequential ROE intensities, and the absence of long-range ROEs. 
Furthermore the amide protons exhibited strong temperature dependence of their chemical shifts 
(Table S1 in supporting information), which is an indicator of high solvent accessibility. 
Altogether, these NMR data indicated that 3β did not adopt per se hydrogen-bonded β-sheet 
conformations and had no self-association properties in solution. Interestingly, 2D NOESY 
experiments recorded on 3β in the presence of Aβ1-42 were characterized by modifications in the 
intensity of intraresidual and sequential NOEs which became more negative (Figure 9S in 
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 supporting information). These changes correspond to transferred NOEs due to transient binding 
of 3β to Aβ1-42 aggregated species. However no additional long-range NOE correlations were 
detected, suggesting that 3β conformation remained largely extended and did not adopt a 
compact shape upon Aβ1-42 binding.  
 
Figure 4. Interaction of 3β with Aβ1-42 monitored by NMR. Aromatic/amide (left) and aliphatic 
(right) regions of 1D 
1
H NMR spectra of 3β (0.4 mM) and Aβ1-42 (90 µM) at 5°C. (A) Reference 
1D 
1
H spectrum recorded at t = 0. (B-E) 1D 
1
H STD spectra recorded at t = 0 (B), after 2 days 
(C), 1 week (D) and 2.5 weeks (E). The assignment of the aromatic and methyl resonances of 3β 
is indicated. Amb means 5-amino-2-methoxybenzoyl. The signal marked with an asterisk 
corresponds to formic acid impurity.  
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 SPR experiments  
SPR was then used to evaluate the affinity between compound 3 and its β-anomer 3β and Aβ1-
42 monomer bound to the gold surface.  
To our knowledge, the few SPR experiments described in the literature to detect the affinity of 
ligands for Aβ1-42 have used either the depsi-peptide molecule described by Taniguchi et al.
36,37,22
 
or biotinylated Aβ1-42 immobilized onto streptavidin-coated chips.
38
 An SPR-based immunoassay 
has been also developed to recognize Aβ1-42 oligomers.
39
 The main drawbacks we found in these 
methods are the necessity to synthesize the non-commercial depsi-peptide, the modest SPR 
response provided with these other approaches, and the use of modified peptides which may alter 
their affinity behavior. We thus developed a new method to immobilize the commercial Aβ1-42 
peptide monomer by a classical peptide coupling through its amino groups. We paid particular 
attention to maintaining Aβ1-42 in its monomeric form upon immobilization. Recently a similar 




We optimized the immobilization of Aβ1-42 peptide by varying different parameters (pH and 
concentration of the sample preparation, and injection parameters such as the flow, the time and 
the number of injections). To ensure that only monomeric species were mainly immobilized, a 
rinsing step using an aqueous solution of NH4OH.H2O 0.1 % was employed (see the procedure 
in supporting information), as we demonstrated previously by CE that these conditions were able 
to disaggregate oligomers and regenerate monomeric species.
32
 The characterization of the gold 
chip was performed using specific antibodies directed against the N- or C-term of Aβ1-42 (6E10 
and MD 19-0016, respectively, see supporting information). Curcumin, which is a well-known 
disaggregant compound
41
 did not lead to a decrease of the signal and was even found to bind to 
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 Aβ1-42 fixed on the SPR chips (Figure 18S in supporting information). Finally, the affinity of ThT 
toward the peptide immobilized on the chip surface was evaluated before and after our optimized 
rinsing step, which used an aqueous solution of NH4OH.H2O 0.1 %. Both SPR signal and 
fluorescence (visualized by fluorescence microscopy images of the channel) were higher before 
the rinsing step. The rinsing step is therefore crucial to disaggregate large species present 
initially on the chip surface in order to lead to a surface mainly composed by Aβ in its 
monomeric form (Figure 14S in supporting information).  
We conducted SPR measurements with compounds 3, 3β and 1 to check their affinity for Aβ1-
42 peptide. A concentration-dependent signal was observed, however, the response was very low 
in the range of the tested concentrations (up to 200 µM) indicating that these compounds have a 
very low affinity for the immobilized Aβ1-42 (Figures 15S, 16S and 17S in supporting 
information). This result is in accordance with the NMR data.  
 
Protection against Aβ1-42 cell toxicity  
The inhibitors were investigated to determine their ability to reduce the toxicity of aggregated 
Aβ1-42 to SH-SY5Y neuroblastoma cells. The addition of either 1 or 3 showed a protective effect 
on cell survival (MTS assay, Figure 5) and membrane damage (LDH membrane integrity assay, 
Figure 19S in supporting information) in the presence of cytotoxic 5 µM Aβ1-42. Remarkably, 
this protective effect was seen at equimolar amounts of inhibitor to Aβ1-42 and was still 
significant at a very low ratio of 0.1/1 (inhibitor/Aβ1-42) in the MTS assay. 
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Figure 5. Effect of 1 and 3 on Aβ1-42 toxicity towards SH-SY5Y cells. Cell viability in the 
presence of 5 µM aggregated Aβ1-42 and decreasing concentrations of 1 or 3. The black bar on 
the left shows cell viability in the absence of Aβ1-42. Statistical significance is indicated by *, 
where * is p<0.05, ** is p<0.01 and *** is p<0.001 comparing cells incubated with Aβ1-42 plus 
inhibitor to those with Aβ1-42 alone. Statistical significance is described. 
 
Plasma stability 
The ability to withstand enzymatic cleavage in the circulatory system is an important 
requirement for any potential drug. Incubating the two inhibitors 1 and 3 in plasma gives an idea 
of how stable they will be once injected into the body. 3 withstood 24 hours at 37˚C with no 
obvious degradation in 10% plasma (Figure 20S in supporting information). 1 appeared to show 
some degradation over the same period, although the total area of the peaks did not change 
(Figure 20S in supporting information). Unmodified polypeptides are usually degraded within 
minutes under these incubation conditions. 
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The introduction of a peptidomimetic strand based on a 5-amino-2-methoxybenzhydrazide unit 
linked through the carboxyethyl in the C6 position of the D-glucopyranosyl scaffold not only 
increased the stability towards proteolytic degradation but also dramatically increased the 
capacity of these pentapeptide analogs to inhibit the fibrillization of Aβ1-42, as demonstrated by 
the ThT fluorescence and TEM experiments. The polar hydroxyl groups of the sugar moiety 
were essential to prevent the aggregation, as demonstrated by the lack of inhibitory activity of 
the benzyl analogues 19, 22-23. A slightly superior effect was observed for the β anomer 3β 
compared to the mixture of α and β anomers in 3 (confirmed in the CE experiments). The 
presence of the amine of the side chain of the lysine residue in compound 3 proved to be 
beneficial for the inhibitory activity in comparison with the valine residue in compound 2. This 
result suggests that an ionic interaction is likely to be established between this amine and acidic 
residues of Aβ1-42, strengthening the hydrophobic interactions involving aliphatic and aromatic 
moities. Indeed, several computational and experimental studies on Aβ1-42 have shown that, in 
addition to the hydrophobic interactions involving in particular the 16-21 sequence (KLVFFA), 
the formation of a salt-bridge between amino acids Asp23 and Lys28 might stabilize a turn motif 
involving residues 24-28.
9,42
 An interaction with Glu22 might also be beneficial for the activity 
of the molecules.
42b 
We can thus suggest, and this is supported by the NMR binding experiments 
(STD), that this novel class of glycopeptidomimetics is likely to interact through the hydrophobic 
sequences of the peptidomimetic and dipeptide sequences, presumably with a hydrophobic 
sequence of Aβ1-42 (such as the central K16-A21 or the C-terminal part I31-V40) and through an 
electrostatic interaction. The flexible and hydrophilic sugar moiety acts as a β-sheet breaker to 
prevent the aggregation. The effect of the glycopeptidomimetic on the early steps of 
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 oligomerization has been also demonstrated clearly by CE. Compound 3β dramatically preserved 
the non-toxic monomer of Aβ1-42 (ES). Oligomers larger than dodecamers (LS) were also 
stabilized. Both types of cell viability assay proved that pre-incubation of cytotoxic Aβ1-42 with 
glycopeptidomimetic 3 completely rescued the SH-SY5Y neuroblastoma cells. The protective 
effect was observed even at sub-stoichiometric concentrations (3 reduced cell death by 100% 
with 0.5 eq and by 75% with 0.1 eq. in the MTS assay). This protective effect is much more 







 or other molecules 
recently described as efficient reducers of Aβ1-42 toxicity.
46
 This effect is comparable to the best 
effect of the current Aβ aggregation inhibitors reported in the literature.
22
 Indeed, these 
molecules reduced Aβ1-42 toxicity only at stoichiometric or higher (5 to 10 equivalents) 
concentrations. It is also noteworthy that glycopeptide 1 showed a dramatic effect on cell 
survival, but was more sensitive to proteolytic attack.  
The NMR and SPR experiments clearly indicated that this novel glycopeptidomimetic series 
does not bind to monomers with substantial affinity. NMR indicated that the Aβ1-42 species 
recognized by 3β are oligomeric forms whose concentration slowly increased with time. Thus, 
even if 3β is a small molecule that does not per se adopt a preferential conformation, it is able to 
recognize and bind to the early β-structured Aβ1-42 oligomers. The observation of magnetization 
transfers in STD, WaterLOGSY and trNOESY experiments implied that the interconversion 
between the free and the Aβ1-42-bound forms of 3β occurred in fast exchange on the NMR time 
scale. We can thus hypothesize that such transient binding of 3β to oligomers may impede the 
subsequent addition of monomers or the association of oligomers into larger species and/or 
disrupt these early oligomers so that they revert back to monomers (Figure 6A).  
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Figure 6. Hypothesis of mechanism of Aβ1-42 aggregation inhibition by 3β. A- Proposed model 
of inhibition of fibrillization of Aβ1-42 and of preservation of Aβ1-42 monomer by 3β. B- Proposed 
model of interaction of 3β with Aβ1-42.  
 
Noteworthy, this inhibition effect is sequence-specific since compound 3 does not alter the 
kinetics of aggregation of another amyloid peptide, IAPP, involved in type 2 diabetes mellitus. 
Indeed, the peptidomimetic 3 does not inhibit the IAPP fibril formation even at a high 
peptidomimetic/ IAPP ratio of 10/1 (see supporting information). The t1/2 is not increased after 
addition of 3 and the final fluorescence intensity remains the same. 
 
Page 24 of 58
ACS Paragon Plus Environment






























































In conclusion, the present work validates the singular effect of sugar-based peptidomimetic 
analogs of pentapeptides on Aβ1-42 oligomerization and fibrillization. This new series has been 
designed in order to achieve three objectives: first, to engage hydrophobic, hydrogen bonds and 
ionic interactions with Aβ1-42, thanks to small peptide and peptidomimetic arms; secondly, to 
prevent cross β-sheet elongation of Aβ1-42 due to the hydrophilic sugar, considered as a β-sheet 
breaker element (Figure 6B). Finally, it has been designed also to be druggable, particularly to be 
a small molecule (MW around 800) with a good hydrophobicity/ hydrophilicity balance and 
resistance to proteolytic degradation. A wide range of bio- and physico-chemical techniques was 
used to demonstrate the capacity of the compounds (in particular 3β) to delay both the early 
oligomerization and fibrillization of Aβ1-42. To the best of our knowledge, this is the first 
example of a small molecule being able to preserve the non-toxic monomeric species of Aβ1-42, 
as demonstrated by capillary electrophoresis. The strong protective effect on cells, even at sub-
stoichiometric concentrations, also highlights the considerable therapeutic potential of this novel 
series of peptidomimetics. This protective effect is significantly better that the one observed with 
molecules which have undergone clinical trials. The structural elements demonstrated here as 
crucial for the inhibitory activity, i.e. hydrophobic moieties, hydrogen bond donors and 
acceptors, ammonium groups and hydrophilic β-sheet breakers provide valuable insights to 
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 General Experimental Methods. Usual solvents were purchased from commercial sources 






 were prepared 
according to published methods. Pure products were obtained after liquid chromatography using 
Merck silica gel 60 (40-63 µm). TLC analyses were performed on silica gel 60 F250 (0.26 mm 
thickness) plates. The plates were visualized with UV light (λ = 254 nm) or revealed with a 4 % 
solution of phosphomolybdic acid in EtOH. Melting points were determined on a Kofler melting 
point apparatus. Element analyses (C, H, N) were performed on a Perkin-Elmer CHN, Analyser 
2400 at the Microanalyses Service of the Faculty of Pharmacy at Châtenay-Malabry (BioCIS, 
France). NMR spectra were recorded on an ultrafield Bruker AVANCE 300 (
1
H, 300 MHz, 
13
C, 
75 MHz) or on a Bruker AVANCE 400 (
1
H, 400 MHz, 
13
C, 100 MHz). Chemical shifts δ are in 
ppm and the following abbreviations are used: singlet (s), doublet (d), doublet of doublet (dd), 
triplet (t), quintuplet (qt), multiplet (m), broad multiplet (bm), and broad singlet (bs). Mass 
spectra were obtained using a Bruker Esquire electrospray ionization apparatus. HRMS were 
obtained using a TOF LCT Premier apparatus (Waters), with an electrospray ionization source. 
The purity of compounds 2, 19-23 was determined by HPLC using the 1260 Infinity system 
(Agilent Technologies) and a column SUNFIRE (C18, 3.5 µm, 100 mm X 2.1 mm); mobile 
phase : MeOH / H2O + 0.1 % formic acid from 5 to 100 % in 20 min. ; detection at 254 nm ; 
flow rate 0.25 mL/min. The purity of compounds 3 and 3β was determined by HPLC using the 
1260 Infinity system (Agilent Technologies) and a column SUNFIRE (C18, 5 µm, 150 mm X 
2.1 mm); mobile phase for 3 : acetonitrile / H2O + 0.2 % formic acid  from 1 to 100 % in 20 min. 
; mobile phase for 3β: acetonitrile / H2O + 0.2 % formic acid at ratio 1/99 during 3 min., then 
gradient to 30/70 in 12 min.; detection at 310 nm ; flow rate 0.25 mL/min.  
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butanamide (2). Same procedure as described for 16a from 20 (35 mg, 0.036 mmol) in dry 
CH₂Cl₂ (300 µL) to yield 2 (38 mg, quantitative, α/β 60/40) as a white solid. Rf = 0 (CH₂Cl₂/ 
CH₃OH : 95/5) ; ¹H NMR (300 MHz, CD3OD) : δ = 7.88 (d, J = 2.7 Hz, 1H); 7.53 (dd, J = 9.0, 
2.7 Hz, 1H); 6.90 (d, J = 9.0 Hz, 1H); 4.54 (d, J = 3.6 Hz, 0.60H, H1β);  4.19 (d, J = 7.0 Hz, 1H,); 
4.05 (d, J = 7.8 Hz, 0.40H, H1α); 3.96 (dd, J = 7.7, 2.7 Hz, 1H); 3.86 (m, 1H); 3.76 (s, 3H); 3.64 
– 2.96 (m, 12H); 2.36 (m, 2H); 1.96 (m, 1H); 1.91 (s, 3H); 1.81 (m, 1H); 1.58 (m, 2H); 1.29 (d, J 
= 7.0 Hz, 3H); 0.84 (m, 6H); 0.74 (d, J = 6.7 Hz, 6H) ; 
13
C NMR  (75 MHz, CD3OD) : δ = 174.2, 
174.1, 173.0, 171.6, 171.0, 165.5, 155.6, 133.3, 126.8, 124.3, 120.9, 113.4, 104.3 (C1Hα), 100.2 
(C1Hβ), 77.9, 76.6, 75.0, 73.4, 72.5, 71.6, 71.1, 68.5, 68.4, 67.1, 60.7, 58.7, 57.0, 50.1, 37.8, 37.6, 
37.3 (C8), 31.9, 30.0, 23.7, 19.7, 18.7, 17.7; HRMS (TOF, ESI, ion polarity positive, H2O/ 
MeOH): m/z [M+H]
+
, calcd for C35H58N7O13 784.4093; found 784.4094, m/z [M+Na]
+
, calcd for 




butanamide (3). Same procedure as described for 16a from 21 (38 mg, 0.040 mmol) in dry 
CH₂Cl₂ (300 µL) to afford 3 (40 mg, quantitative, α/β 50/50) as a white solid. Rf = 0 (CH₂Cl₂/ 
CH₃OH : 95/5); ¹H NMR (300 MHz, CD3OD) : δ = 8.16 (sl, 1H); 7.70 (m, 1H); 7.14 (d, J = 9.0 
Hz, 1H); 4.75 (m, 0.50H, H1β); 4.54 (m, 1H); 4.26 (d, J = 7.8 Hz, 0.50H, H1α); 4.14 (m, 1H); 4.02 
(d, J = 7.1 Hz, 1H); 3.98 (s, 3H); 3.90 (m, 1H); 3.79 (m, 3H);  3.70 (m, 1H); 3.62 (m, 2H); 3.35 
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 (m, 4.6H); 3.16 (m, 0.6H); 3.04 (m, 1H); 2.98 (m, 1H); 2.55 (sl, 2H); 2.12 (s, 3H); 2.03 (m, 1H); 
1.90 (m, 2H); 1.77 (m, 4H); 1.57 (m, 2H); 1.50 (d, J = 7.1 Hz, 3H); 1.34 (d, J = 6.5 Hz, 4H); 
0.97 (d, J = 6.5 Hz, 6H) ; 
13
C NMR  (125 MHz, H2O:D2O 90:10) : δ = 177.5, 177.1, 175.9, 
175.6, 173.6, 169.5, 169.2, 165.6, 158.1, 132.8, 131.5, 131.4, 130.18, 127.8, 121.4, ,121.2, 120.1, 
117.8, 115.6, 104.9 (C1Hα), 103.0, 100.9 (C1Hβ), 78.3, 77.3, 75.8, 73.1, 72.4, 72.1, 71.5, 70.3, 
69.9, 69.8, 68.1, 63.1, 58.8, 55.6, 55.27, 53.5, 51.6, 47.3, 42.1, 42.0, 39.2, 39.0, 38.5, 38.3, 34.1, 
33.2, 33.1, 32.6, 31.1, 31.0, 29.2, 29.1, 28.2, 25.3, 24.9, 24.7, 21.1, 21.0, 20.8, 19.5 ; HRMS 
(TOF, ESI, ion polarity positive, H2O/ MeOH): m/z [M+H]
+
, calcd for C36H61N8O13 813.4358; 




butanamide (3β). Isolation of β anomer 3β from 3 was performed by HPLC using a WATERS 
gradient system pump (DELTAPREP, UV detector PDA 2996) and a column sunfire (C18, 5 
µm, 150 mm x 19 mm); mobile phase: acetonitrile /H2O + 0.2 % formic acid at ratio 1/99 during 
3 min., then at ratio 60/40 in 12 min. ;  flow rate 17 mL/min. ; detection at 310 nm. HRMS 
(TOF, ESI, ion polarity positive, H2O/ MeOH): m/z [M+H]
+
, calcd for C36H61N8O13 813.4358; 




C NMR assignments are 
shown in supporting information (Tables S1 and S2) 
tert-Butyl 3-[(6-allyloxy-3,4,5-tribenzyloxy-tetrahydropyran-2-yl)methoxy]propanoate 
(5). To a suspension of 4 (7.00 g, 14.27 mmol) in tert-butyl-acrylate (4.14 mL, 28.54 mmol) was 
added TBAB (690 mg, 2.14 mmol) and an aqueous solution of NaOH 20% (60 mL). The 
reaction mixture, which appeared like an emulsion, was stirred for 24 h at room temperature. At 
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 the end of the reaction, a mixture of EtOAc/H₂O 1/1 (200 mL) was added and the aqueous phase 
was extracted with EtOAc (3 x 60 mL). The combined organic layers were dried over Na₂SO₄, 
filtered and concentrated under reduced pressure to give a crude oil which was purified by 
column chromatography on silica gel with eluent cyclohexane/EtOAc 80/20 to afford 5 as a 
colourless oil (7.1 g, 79%, α/β 70/30). Rf = 0.45 (cyclohexane/EtOAc : 80/20); ¹H NMR (300 
MHz, CDCl₃) : δ = 7.34 (m, 15H); 5.93 (m, 1H); 5.32 (dd, J = 17.2, 1.5 Hz, 1H); 5.22 (d, J = 
10.0 Hz, 1H); 4.86 (d, J = 4.9 Hz, 0.75H, H1β); 4.45 (d, J = 7.8 Hz, 0.25H, H1α); 5.10-4.54 (m, 
6H), 4.25-3.47 (m, 10H); 2.52 (t, J = 6.3 Hz, 2H); 1.45 (s, 9H); 
13
C NMR  (75 MHz, CDCl3) : δ 
= 170.7, 138.9, 138.4, 138.2, 133.8, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.7, 127.5, 
118.2, 95.7, 82.1, 80.5, 79.9, 77.6, 75.7, 75.0, 73.2, 70.2, 69.5, 68.2, 67.1, 36.1, 28.1; Anal. 
Calcd for C37H46O8: C, 71.82; H, 7.49; Found C, 71.75; H, 7.65; MS (ESI, ion polarity positive, 




(6). To a stirred mixture of 5 (7.10 g, 11.47 mmol) in CH₃OH /EtOH 2/1 (60 mL) was added 
PdCl₂ (170 mg, mass 2.4%) at room temperature. The brown suspension was stirred under azote 
atmosphere overnight and became darker and finally black. The reaction mixture was filtered 
through a pad of Celite which was washed several times with CH₃OH. The filtrate was then 
concentrated under reduced pressure to obtain a brown oil, which was purified by column 
chromatography on silica gel with eluent cyclohexane/EtOAc 90/10 to yield 6 as a yellow oil 
(4.61 g, 75%, α/β 70/30). Rf = 0.15 (cyclohexane/EtOAc : 90/10) ; ¹H NMR (300 MHz, CDCl₃) : 
δ = 7.32 (m, 15H); 5.32 (s, 0.70H, H1β); 5.04- 4.56 (m, 6.30H, 6H+H1α); 4.22-3.36 (m, 8H); 2.52 
(t, J = 6.5 Hz, 2H); 1.45 (s, 9H) ; 
13
C NMR  (75 MHz, CDCl3) : δ = 170.7, 138.9, 138.4, 138.2, 
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 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.7, 127.5, 95.7, 82.1, 80.5, 79.9, 77.6, 75.7, 75.0, 






To a solution of 6 (4.61 g, 7.96 mmol) in dry CH₂Cl₂ (80 mL) 
cooled at 0°C was gradually added under azote atmosphere NaH (60% dispersion in mineral oil, 
180 mg; 4.50 mmol). Then trichloroacetonitrile (3.8 mL, 38.06 mmol, 11 eq.) was added. After 
20 minutes, the ice bath was removed and the reaction mixture was let to stir at room 
temperature for 4 hours. The solution turned from yellowish to orange while stirring and finally 
became brown. After stirring overnight, the solvent was evaporated under reduced pressure and 
the crude residue was purified by column chromatography on neutral alumina with eluent 
cyclohexane/EtOAc 80/20 to give 7 as a yellow oil (4.31 g, 75%, α/β 85/15). Rf = 0.45 
(cyclohexane/EtOAc : 80/20) ; ¹H NMR (300 MHz, CDCl₃) : δ = 8.59 (s, 1H); 7.31 (m, 15H); 
6.53 (d, J = 3.4 Hz, 0.84H, H1β); 5,03-4.61 (m, 6.16H, 6H+H1α); 4,27-3.48 (m, 8H); 2.51 (t, J = 
6.6 Hz, 2H); 1,44 (s, 9H).  
tert-Butyl 3-((6-(3-azidopropoxy)-3,4,5-tris(benzyloxy)-tetrahydropyran-2-yl)methoxy) 
propanoate (8). To a stirred solution of 7 (4.31 g, 5.96 mmol) and 3-azidopropan-1-ol (723 mg, 
7.15 mmol) in dry CH₂Cl₂ (15 mL) under azote atmosphere, was added AuCl (181 mg, mass 
10%). The reaction mixture was stirred for 2 days at room temperature under azote atmosphere. 
Upon completion of the reaction monitored by TLC, the mixture was filtered to remove the 
catalyst and the filtrate was concentrated under reduced pressure. The oily residue afforded was 
purified by column chromatography on silica gel with eluent cyclohexane/EtOAc 80/20 to give 8 
as a yellow oil (3.25 g, 82%, α/β 50/50). Rf = 0.45 (cyclohexane/EtOAc : 80/20) ; ¹H NMR (300 
MHz, CDCl₃) : δ = 7.33 (m, 15H); 5.08-4.55 (m, 6.50H, 6H+H1β); 4.38 (d, J = 7.8 Hz, 0.50H, 
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 H1α); 4.13-3.23 (m, 12H); 2.51 (t, J = 6.6 Hz, 2H); 1.91 (m, 2H); 1.45 (s, 9H) ; 
13
C NMR  (75 
MHz, CDCl3) : δ = 170.8, 138.9, 138.6, 138.4, 138.2, 128.4, 128.3, 128.0, 127.8, 127.6, 103.6 
(C1Hα), 97.2 (C1Hβ), 84.7, 82.3, 82.0, 80.5, 80.1, 77.8, 76.6, 75.6, 75.1, 74.9, 73.3, 70.4, 69.8, 
69.5, 67.3, 66.6, 64.7, 48.4, 36.3, 36.1, 29.3, 28.9, 28.1, 27.0 ;  IR (neat) : 2096 (N₃); 1728 
(C=O); 1366 (CH₃); 1066 (C-O) cm
-1
 ; Anal. Calcd for C37H47N3O8 
. 
0.5 H2O : C, 66.25; H, 7.23; 





acid (9). To a stirred solution of 8 (3.21 g, 4.85 mmol) in dry CH₂Cl₂ (40 mL) cooled at 0°C was 
cautiously added TFA (18.6 mL, 250.40 mmol). The reaction mixture appeared like a yellow 
solution and was stirred overnight at room temperature. The day after, the solvent was 
evaporated under reduced pressure and the crude residue was purified by column 
chromatography on silica gel beginning with CH₂Cl₂ 100% as eluent and finishing with an eluent 
mixture CH₂Cl₂/CH₃OH 95/5 to provide 9 as a yellow oil (2.11 g, 72%, α/β 50/50). Rf = 0.40 
(CH₂Cl₂/CH₃OH  95/5) ; ¹H NMR (300 MHz, CDCl₃) : δ = 7.32 (m, 15H); 6.93 (s, 1H); 5.04-
4.54 (m, 6.50H, 6H+H1β); 4.40 (d, J = 7.8 Hz, 0.50H, H1α); 4.08-3.32 (m, 12H); 2.63 (m, 2H); 
2.03-1.71 (m, 2H) ; 
13
C NMR  (75 MHz, CDCl3) : δ = 175.4, 138.8, 138.5, 138.4, 138.2, 138.1, 
128.4, 128.0, 127.9, 127.6, 103.6 (C1Hα), 97.2 (C1Hβ), 84.6, 82.2, 82.0, 80.1, 75.7, 75.1, 74.9, 
74.6, 73.3, 70.2, 69.9, 69.7, 66.6, 64.8, 48.3, 34.7, 34.5, 29.3, 28.9; IR (neat) : 2097 (N₃); 1714 
(C=O); 1065 (C-O) cm
-1





tetrahydropyran-2-yl]methoxy]propanamide (12). To a stirred solution of 10 (360 mg, 0.83 
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 mmol) in dry DMF (5 mL) and cooled at 0°C under azote atmosphere, were successively added 
DMTMM (270 mg, 0.83 mmol) and NMM (272 µL, 2.48 mmol). The reaction mixture was 
stirred at 0°C for 1h. Then, 9 (500 mg, 0.83 mmol) in dry DMF (5 mL) was added to the reaction 
mixture. The ice bath was removed after 30 minutes and the orange reaction mixture was stirred 
at room temperature overnight. The solvent was evaporated under reduced pressure and the oily 
residue was taken up with EtOAc (50 mL). The organic layer was successively washed with 
distilled water, 10% citric acid aqueous solution, 10% aqueous K₂CO₃ solution and brine, dried 
over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The yellow crude 
product was purified by puriflash column chromatography (SI-HP, 12 g, 22 bars, 30 µm, flow 
rate: 20 mL/min) with eluent CH₂Cl₂/CH₃OH 95/5 to afford 12 as a white solid (593 mg, 86%, 
α/β 40/60); mp = 71-73 °C ; Rf = 0.60 (CH₂Cl₂/CH₃OH  95/5) ; ¹H NMR (300 MHz, CDCl₃) : δ 
=  12.05 (t, J = 6.2 Hz, 1H, NH); 11.28 (d, J = 6.3 Hz, 1H, NH); 9.80 (s, 1H); 8.58 (dd, J = 9.1, 
2.4 Hz, 1H); 8.27 (d, J = 2.4 Hz, 1H); 7.33-7.19 (m, 15H); 7.07-6.95 (m,2H); 5.30 (m, 1H); 4.94-
4.58 (m, 6.40H, 6H+H1β); 4.40 (d, J = 7.8 Hz, 0.60H, H1α); 4.02-3.44 (m, 15H); 2.59 (m, 2H); 
2.19 (s, 3H); 2.09-2.01 (m, 1H); 1.94-1.83 (m, 2H); 0.91-0.96 (m, 6H) ; 
13
C NMR  (75 MHz, 
CDCl3) : δ = 171.2, 171.1, 169.0, 164.9, 158.2, 158.1, 153.1, 138.9, 138.6, 138.4, 138.3, 138.2, 
138.1, 133.9, 128.4, 128.3, 128.0, 127.9, 127.8, 127.5, 124.7, 122.5, 117.7, 111.8, 103.6 (C1Hα), 
97.1 (C1Hβ), 84.6, 82.3, 81.9, 80.3, 77.8, 77.7, 75.5, 75.1, 75.0, 74.9, 73.1, 70.3, 70.1, 69.7, 67.7, 
67.6, 66.6, 64.8, 56.4, 55.8, 48.3, 37.6, 37.5, 33.4, 33.3, 29.3, 28.9, 24.3, 18.9, 18.2 ; IR (neat) : 
3375 (N-H); 2097 (N₃) cm
-1
; Anal. Calcd for C48H59N7O11 
. 
0.5 H2O : C, 62.73; H, 6.58; N, 10.67 
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yl]methoxy] propanoylamino]hexyl]carbamate (13). Same procedure as described for 12 from 
11b (495 mg, 0.826 mmol) and 9 (500 mg, 0.826 mmol). The yellow crude product obtained was 
purified by puriflash column chromatography (SI-HP, 12 g, 22bar, 30 µm, flow rate: 20 mL/min) 
with eluent CH₂Cl₂/CH₃OH 95/5 to afford 13 as a white solid (593 mg, 68%, α/β 50/50). Rf = 
0.15 et 0.25 (two diastereoisomers) (CH₂Cl₂/CH₃OH  95/5) ; ¹H NMR (300 MHz, CDCl₃) : δ = 
11.97 (sl, 1H, NH) ; 11.32 (sl, 1H, NH); 9.80 (sl, 1H, NH); 8.58 (d, J = 7.7 Hz, 1H); 8.17 (s, 
1H); 7.32 - 7.26 (m, 21H); 6.91 (m, 1H); 5.41 (m, 1H); 5.07 – 4.60 (m, 9.50H, 9H+H1β); 4.42 (d, 
J = 7.8 Hz, 0.50H, H1α); 4.11 – 3.32 (m, 15H); 2.99 (m, 2H); 2.59 (s, 2H); 2.21 (s, 3H); 1.88 (m, 
2H); 1.37 (m, 6H) ; 
13
C NMR  (75 MHz, CDCl3) : δ = 174.2, 173.3, 169.2, 165.5, 156.3, 153.3, 
138.5, 138.0, 137.8, 136.7, 133.8, 128.5, 128.3, 128.0, 127.8, 125.0, 122.1 (C30), 117.7, 111.9, 
103.6 (C1Hα), 97.2 (C1Hβ), 92.2, 87.2, 84.6, 82.0, 81.7, 75.6, 66.7 (C16), 56.4, 50.8, 48.3, 40.6, 








To a stirred solution of 12 (174 mg, 0.19 mmol) in THF (2 mL) 
was added at room temperature Ph3P (100 mg, 0.38 mmol). After 10 minutes, H2O (0.3 mL) was 
added and the reaction was stirred at reflux at 40°C for 24 h. The solvents were evaporated under 
reduced pressure and the oily residue obtained was purified by column chromatography on silica 
gel successively eluting with CH₂Cl₂ 100%, then CH₂Cl₂/CH₃OH 95/5,  CH₂Cl₂/CH₃OH 90/10 
to eliminate the impurities and finally with CH₂Cl₂/CH₃OH/ NH4OH (20% aq. sol.) 88/9/3 to 
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 afford 14 (107 mg, 63%, α/β 40/60) as a white solid; mp = 203-205 °C ; Rf = 0.10 
(CH₂Cl₂/CH₃OH/NH4OH (20% aq. sol.) 88/9/3 ; ¹H NMR (300 MHz, CDCl₃) : δ = 9.71 (bs, 
1H); 8.55 (dd, J = 9.1, 2.7 Hz, 1H); 8.25 (d, J = 2.7 Hz, 1H); 7.31-7.20 (m, 16H); 6.92 (d, J = 
9.1, 1H); 5.25 (m, 1H); 4.89-4.57 (m, 6,40 H, 6H+H1β); 4.41 (d, J = 7.8 Hz, 0.60H, H1α); 3.94 (s, 
3H); 3.91 – 3.36 (m, 12H); 2.85 (m, 2H); 2.58 (m, 2H); 2.17 (s, 3H); 2.08 (m, 1H); 1.78 (m, 2H); 
0.91 (m, 6H) ; 
13
C NMR  (75 MHz, CDCl3) : δ = 171.3, 169.0, 165.4, 158.4, 153.1, 138.6, 138.5, 
138.0, 133.9, 128.4, 128.3, 128.0, 127.8, 127.6, 127.5, 124.8, 122.5, 117.8, 111.8, 103.6, 84.6, 
82.3, 77.9, 75.5, 75.0, 74.8, 70.2, 67.7, 56.4, 56.0, 38.9, 37.5, 33.2, 33.0, 24.3, 19.0, 18.3 ; IR 
(neat) : 3465, 3418 (HN-H) cm
-1
; Anal. Calcd for C48H61N5O11 
. 
(CH3)2CO : C, 65.02; H, 7.18; N, 






hexyl]carbamate (15). Same procedure as described for 14 from 13 (497 mg, 0.463 mmol) to 
afford 15 (247 mg, 50%, α/β 50/50) as a white solid. Rf = 0.1 (CH₂Cl₂/CH₃OH/NH4OH (20% aq. 
sol.) 88/9/3) ; ¹H NMR (300 MHz, CD3OD) : δ = 8.08 (dd, J = 12.4, 2.7 Hz, 1H); 7.70 (m, 1H); 
7.34-7.22 (m, 20H); 6.98 (m, 1H); 4.98 (s, 2H); 4.97 – 4.53 (m, 8.50H, 8H+H1β); 4.41 (m, 1H), 
4.37 (d, J = 7.7 Hz, 0.50H, H1α); 3.86 (s, 3H), 3.80 – 3.21 (m, 10H) 3.04 (m, 2H); 2.85 (m, 2H) 
2.48 (m, 2H); 2.03 (m, 3H); 1.87 – 1.67 (m, 4H); 1.42 (m, 4H) ; 
13
C NMR (75 MHz, CD3OD) : δ 
=  173.9, 171.5, 171.3, 164.6, 164.2, 158.8, 155.5, 140.0, 139.9, 139.6, 139.5, 138.3, 133.5, 
129.4-128.6, 126.6, 126.3, 124.3, 124.2, 121.3, 121.2, 113.4, 104.7 (C1Hα), 98.0 (C1Hβ), 85.6, 
83.4, 83.0, 81.4, 79.1, 78.9, 76.4, 76.0, 75.9, 75.6, 75.3, 74.0, 71.7, 70.7, 68.6, 68.5, 68.3,  67.5, 
67.3,  56.9, 53.8, 53.7, 49.9, 41.5, 39.8, 39.3, 37.5, 37.3, 33.0, 32.9, 30.9, 30.4, 24.0, 23.9, 23.7 ; 
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 HRMS (TOF, ESI, ion polarity positive, H2O/ MeOH): m/z [M+H]
+
, calcd for C57H71N6O13 
1047.5079; found 1047.5063.  
tert-Butyl N-[(1S)-1-[3-[6-[[3-[[(1S)-1-[[(5-acetamido-2-methoxy-benzoyl)amino] 
carbamoyl]-2-methyl-propyl]amino]-3-oxo-propoxy]methyl]-3,4,5-tribenzyloxy-
tetrahydropyran-2-yl]oxypropylcarbamoyl]-2-methyl-propyl]carbamate (16). To a stirred 
solution of N-Boc-Val-OH (132 mg, 0.60 mmol) in dry DMF (2 mL) and cooled at 0 °C, under 
azote atmosphere, were successively added DMTMM (98.4 mg, 0.30 mmol) and NMM (100 µL, 
0.91 mmol). The reaction mixture was stirred at 0 °C for 1h. Then 14 (270 mg, 0.30 mmol) in 
dry DMF (2 mL) was added to the reaction mixture. The ice bath was removed after 30 minutes 
and the orange reaction mixture was stirred at room temperature overnight. The solvent was 
evaporated under reduced pressure and the oily residue obtained was taken up with EtOAc (50 
mL). The organic layer was successively washed with distilled water, 10% citric acid aqueous 
solution, 10% K₂CO₃ aqueous solution, and brine, dried over anhydrous Na₂SO₄, filtered and 
concentrated under reduced pressure. The oily crude product was purified by puriflash column 
chromatography (SI-HP, 12 g, 22 bars, 30 µm, flow rate: 20 mL/min) with eluent 
CH₂Cl₂/CH₃OH 95/5 to afford 16 (260 mg, 79%, α/β 40/60) as a white solid. Rf = 0.35 
(CH₂Cl₂/CH₃OH 95/5) ; ¹H NMR (300 MHz, CD3OD) : δ = 8.04 (s, 1H); 7.80 (d, J = 8.8, 2.7 Hz, 
1H); 7.34-7.25 (m, 15H); 7.10 (d, J = 8.8 Hz, 1H); 4.93-4.61 (m, 6.40H, 6H+H1β); 4.44 (d, J = 
7.8 Hz, 0.60H, H1α); 4.34 (d, J = 6.8 Hz, 1H); 3.94 (s, 3H); 3.81-3.29 (m, 13H); 2.61-2.46 (m, 
2H); 2.14-2.09 (m, 4H); 199-1.79 (m, 3H); 1.45 (s, 9H); 1.04 (dd, J = 11.2, 6.7 Hz, 6H); 0.93 (m, 
6H) ; 
13
C NMR  (75 MHz, CD3OD) : δ = 174.4, 174.2, 171.5, 171.4, 157.9, 155.6, 140.3, 139.9, 
139.6, 133.5, 129.5, 129.3, 129.0, 128.9, 128.6, 128.5, 126.7, 124.3, 121.2, 113.4, 104.8 (C1Hα), 
98.1 (C1Hβ), 83.0, 81.4, 78.9, 76.4, 76.0, 75.9, 75.8, 73.9, 71.6, 70.5, 68.6, 67.4, 61.8, 58.9, 57.0, 
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propyl]amino]-1-methyl-2-oxo-ethyl]carbamate (17). Same procedure as described for 16 
from 15 (245 mg, 0.234 mmol) to afford 17 as a white solid (200 mg, 68%, α/β 50/50). Rf = 0.35 
et 0.40 (two diastereoisomers) (CH₂Cl₂/CH₃OH : 95/5) ; ¹H NMR (300 MHz, CD3OD) : δ = 8.06 
(s, 1H) ; 7.83 (m, 1H); 7.29-7.23 (m, 20H); 7.04 (dd, J = 9.0, 3.6 Hz, 1H); 5.03 (m, 2H); 4.91 – 
4.57 (m, 6.50H, 6H+H1β); 4.51 (m, 1H); 4.40 (d, J = 7.8 Hz, 0.50H, H1α); 3.88 (s, 3H); 3.84 – 
3.48 (m, 10H); 3.43-3.28 (m, 3H); 3.08 (m, 2H); 2.53 (m, 2H); 2.08 (m, 3H); 2.00 – 1.78 (m, 
5H); 1.49 (m, 4H); 1.42 (s, 9H); 0.90 (m, 6H) ; 
13
C NMR  (75 MHz, CD3OD) : δ = 174.3, 174.1, 
174.0, 172.1, 171.4, 165.3, 158.8, 157.8, 155.5, 140-139.6, 138.4, 133.6, 129.4- 128.5, 126.8, 
124.3, 120.9, 113.4, 104.8 (C1Hα), 98.1 (C1Hβ), 85.7, 83.5, 83.0, 81.6, 80.5, 79.1, 76.5, 76.0, 75.7, 
73.9, 71.6, 70.8, 70.6, 68.5, 67.3, 61.7, 61.6, 57.0, 53.3, 41.5, 37.6, 32.8, 32.7, 32.1, 30.7, 30.4, 
28.7,  24.0, 23.9, 23.7, 19.8, 18.6 ; MS (ESI, ion polarity positive, MeOH) : m/z: 1268.61 
[M+Na]
+
. HRMS (TOF, ESI, ion polarity positive, H2O/ MeOH): m/z [M+Na]
+
, calcd for 




methyl-2-oxo-ethyl]carbamate (18). To a stirred solution of 16 (270 mg, 0.25 mmol) in dry 
CH₂Cl₂ (2 mL), cooled to 0 °C was carefully added TFA (1 mL). After 30 minutes the ice bath 
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 was removed and the reaction mixture was stirred at room temperature for 3 h. The solvent was 
evaporated at reduced pressure and the viscous oily residue was taken up with toluene and again 
evaporated. The oily residue obtained was triturated in Et2O to yield the TFA salt of the free 
amine 16a (301 mg, quantitative, α/β 50/50) as a white solid. Rf = 0 (CH₂Cl₂/CH₃OH : 95/5) ; ¹H 
NMR (300 MHz, CD3OD) : δ = 8.06 (m, 1H); 7.72 (dd, J = 8.7, 2.8 Hz, 1H); 7.28-7.21 (m, 
15H); 7.03 (dd, J = 9.0, 2.3 Hz, 1H); 4.86-4.56 (m, 6.50H, 6H+H1β); 4.44 (d, J = 7.8 Hz, 0.50H, 
H1α); 4.37 (d, J = 6.9, 1H); 3.91 (s, 3H); 3.80-3.34 (m, 13H); 2.50 (m, 2H); 2.12 (m, 2H); 2.06 (s, 
3H); 1.80 (m, 2H); 1.02-0.95 (m, 12H) ; 
13
C NMR  (75 MHz, CD3OD) : δ = 174.2, 171.4, 171.4, 
169.3, 165.4, 155.5, 140.1, 140.0, 139.9, 139.7, 139.5, 133.5, 129.4, 129.3, 129.2, 129.0, 128.9, 
128.7, 128.5, 126.8, 124.3, 121.0, 113.4, 104.8 (C1Hα), 98.1 (C1Hβ), 85.7, 83.0, 81.4, 80.6, 78.9, 
76.3, 76.1, 75.7, 75.5, 71.6, 73.9, 71.6, 70.6, 68.2, 67.0, 59.9, 58.8, 56.9, 38.0, 37.8, 37.4, 32.0, 




Same procedure as described for 12 from N-Boc-L-Ala-OH (102.6 mg, 0.55 mmol, 2 eq.) and 
16a (300 mg, 0.273 mmol) to afford 18 as a white solid (210 mg, 68%, α/β 50/50). Rf = 0.20 
(CH₂Cl₂/CH₃OH : 95/5) ; ¹H NMR (300 MHz, CD3OD) : δ = 8.04 (d, J = 2.8 Hz, 1H); 7.85 (m, 
1H); 7.40-7.19 (m, 15H); 7.11 (m, 1H); 5.00-4.69 (m, 6.50 H, 6H+H1β); 4.43 (d, J = 7.9 Hz, 
0.50H, H1α); 4.38 (d, J = 6.9 Hz, 1H); 4.22-4.06 (m, 2H); 3.95 (s, 3H); 3.84-3.28 (m, 12H); 2.67-
2.44 (m, 2H); 2.25-2.11 (m, 5H); 1.83 (m, 2H); 1.44 (s, 9H); 1.30 (m, 3H); 1.05 (m, 6H); 0.93 
(m, J = 6.5 Hz, 6H) ; 
13
C NMR  (75 MHz, CDCl3) : δ = 172.8, 172.7, 171.1, 171.0, 169.0, 165.3, 
158.5, 153.1, 138.8, 138.5, 138.4, 138.1,133.7, 128.4, 128.3, 128.2, 127.9, 127.8, 127.7, 127.4, 
124.9, 122.5, 117.8, 111.8, 103.6 (C1Hα), 97.1 (C1Hβ), 84.5, 82.1, 82.0, 80.1, 80.0, 77.7, 75.5, 
75.4, 74.9, 74.7, 74.6, 73.2, 70.2, 70.0, 69.9, 67.9, 67.6, 67.4, 66.7, 58.5, 56.4, 55.9, 50.3, 37.4, 
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 37.3, 33.0, 31.0, 30.9, 29.2, 28.2, 24.2, 19.3, 18.9, 18.2, 17.7 ; HRMS (TOF, ESI, ion polarity 
positive, H2O/ MeOH): m/z [M+Na]
+




propyl]amino]-1-methyl-2-oxo-ethyl]carbamate (19).  
Same procedure as described for 18 from 17 (200 mg, 0.16 mmol) to afford the TFA salt of the 
free amine 17a as a white solid (207 mg, quantitative, α/β 50/50). Rf = 0 (CH₂Cl₂/CH₃OH : 95/5) 
; ¹H NMR (300 MHz, CD3OD) : δ = 8.14 (m, 1H) ; 7.74 (d, J = 9.0 Hz, 1H); 7.35 – 7.23 (m, 
20H); 7.12 (d, J = 9.0 Hz, 1H); 5.03 (s, 2H); 4.88 – 4.48 (m, 7.50H, 7H+H1β); 4.41 (d, J = 7.9 
Hz, 0.50H, H1α); 3.90 (s, 3H); 3.89 – 3.20 (m, 13H); 3.07 (m, 2H); 2.55 (m, 2H); 2.13 (m, 1H), 
2.08 (m, 3H); 1.93– 1.75 (m, 4H); 1.51 (m, 4H); 1.02 (m, 6H) ; 
13
C NMR  (75 MHz, CD3OD) : δ 
= 174.2, 172.2, 171.5, 169.4, 165.5, 158.8, 155.6, 140.1, 139.9, 139.7, 138.4, 133.5, 129.4-128.6, 
126.8, 124.3, 120.9, 113.5, 104.8 (C1Hα), 98.0 (C1Hβ), 85.7, 83.4, 83.0, 81.6, 79.0, 76.5, 76.1, 
75.9, 75.6, 73.9, 71.6, 70.7, 68.5, 68.3, 67.3, 67.0, 59.9, 57.0, 53.4, 41.5, 37.8, 37.5, 32.7, 31.4, 
30.4, 24.0, 23.7, 18.9, 18.1, 18.0; HRMS (TOF, ESI, ion polarity positive, H2O/ MeOH): m/z 
[M+H]
+
, calcd for C62H80N7O14 1146.5763; found 1146.5752.  
Same procedure as described for 12 from N-Boc-L-Ala-OH (59.5 mg, 0.32 mmol) and 17a 
(200 mg, 0.16 mmol) to afford 19 as a white solid (152 mg, 73%, α/β 50/50). Rf = 0.30 
(CH₂Cl₂/CH₃OH : 95/5) ; ¹H NMR (300 MHz, CD3OD) : δ = 8.05 (m, 1H) ; 7.82 (s, 1H) ; 7.38 – 
7.23 (m, 20H); 7.11 (m, 2H); 5.05 (m, 2H); 4.91 – 4.59 (m, 6.50H, 6H+H1β); 4.49 (m, 1H); 4.40 
(d, J = 7.8 Hz, 0.50H, H1α); 4.10 (m, 2H); 3.92 (s, 3H); 3.89 (m, 1H); 3.76 – 3.31 (m, 11H); 3.09 
(s, 2H); 2.54 (s, 2H); 2.09 (m, 3H); 2.02 (m, 1H); 1.91 – 1.78 (m, 4H,); 1.49 (m, 4H); 1.41 (s, 
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 9H); 1.28 (s, 3H); 0.91 (m, 6H) ; 
13
C NMR  (75 MHz, CD3OD) : δ = 175.8, 174.2, 172.2, 172.0, 
171.5, 169.4, 165.5, 164.3, 158.7, 155.7, 140.1, 138.6, 133.5, 129.4,129.3, 129.2, 129.0, 128.9, 
128.5, 126.9, 124.3, 120.9, 113.5, 104.8 (C1Hα), 98.0 (C1Hβ), 83.4, 81.6, 80.8, 79.1, 76.5, 76.1, 
75.9, 73.9, 71.6, 70.7, 68.5, 67.3, 67.2, 60.0, 57.0, 53.4, 51.7, 44.6, 41.5, 37.9, 37.5, 32.6, 32.1, 
30.6, 30.4, 28.7, 23.9, 23.7, 19.1, 18.4, 18.0, 17.9 ; MS (ESI, ion polarity positive, MeOH) : m/z: 
1339,65 [M+Na]
+
. HRMS (TOF, ESI, ion polarity positive, H2O/ MeOH): m/z [M+H]
+
, calcd for 





2-oxo-ethyl]carbamate (20). To a stirred solution of 18 (105 mg, 0.091 mmol) in CH₃OH (3 
mL) was added Pd/C (25 mg, 25% mass). The reaction flask was purged three times with 
hydrogen, and stirring was maintained under hydrogen atmosphere at room temperature for 2 
days. Upon completion of the reaction monitored by TLC, the solution was filtered through a pad 
of Celite which was washed several times with CH₃OH. Then, the filtrate was concentrated 
under reduced pressure to provide 20 (70.7 mg, 88%, α/β 50/50) as a white solid. Rf = 0 (CH₂Cl₂/ 
CH₃OH  : 95/5); ¹H NMR (300 MHz, CD3OD) : δ = 7.97 (s, 1H); 7.77 (dd, J = 9.0, 2.2 Hz, 1H); 
7.07 (d, J = 9.0 Hz, 1H); 4.71 (d, J = 3.6 Hz, 0.50H, H1β); 4.35 (d, J = 6.9 Hz, 1H); 4.21 (d, J = 
7.8 Hz, 0.50H, H1α);  4.08 (m, 1H); 3.93 (s, 3H); 3.75-3.24 (m, 12H); 2.52 (m, 2H); 2.13 (m, 
1H); 2.08 (s, 3H); 2.00 (m, 1H); 1.75 (m, H); 1.39 (s, 9H); 1.26 (d, J = 7.2 Hz, 3H); 1.01 (m, 
6H); 0.89 (d, J = 6.7 Hz, 6H) ; 
13
C NMR  (75 MHz, CD3OD) : δ = 175.6, 174.2, 173.2, 171.7, 
171.6, 165.5, 155.6, 155.6, 133.4, 126.9, 124.3, 121.1, 113.4, 104.3 (C1Hα), 100.2 (C1Hβ), 80.7, 
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 77.9, 76.7, 75.0, 73.4, 72.5, 71.6, 71.5, 71.3, 71.2,  68.7, 68.6, 67.2, 60.1, 58.8, 58.7, 57.0, 51.7, 
37.9, 37.4, 32.0, 32,2, 32.0, 30.0, 28.7, 23.6, 19.7, 18.8, 18.7, 17.9 ; HRMS (TOF, ESI, ion 
polarity positive, H2O/ MeOH): m/z [M+Na]
+
, calcd for C40H65N7O15Na 906.4436; found 




2-oxo-ethyl]carbamate (21). Same procedure as described for 20 from 19 (111 mg, 0.083 
mmol) in CH₃OH (3 mL) except that CH3CO2H was added (1 mL) to provide 21 (61.6 mg, 75%, 
α/β 50/50) as a white solid. Rf = 0 (CH₂Cl₂/ CH₃OH  : 95/5); ¹H NMR (300 MHz, CD3OD) : δ = 
8.12 (s, 1H); 7.73 (s, 1H); 7.13 (d, J = 8.6 Hz, 1H); 4.76 (d, J = 3.6 Hz, 0.50H, H1β); 4.54 (m, 
1H), 4.26 (d, J = 7.6 Hz, 0.50H, H1α); 4.13 (m, 2H); 3.97 (s, 3H); 3.89 – 3.57 (m, 6H); 3.34 – 
3.26 (m, 5H); 3.17 (m, 1H); 2.97 (m, 2H); 2.55 (m, 2H); 2.12 (s, 3H); 2.04 (m, 1H); 1.96 (s, 8H, 
2H + CH3CO2H); 1.78 (m, 4H); 1.56 (m, 2H); 1.43 (s, 9H); 1.29 (m, 3H); 0.93 (d, J = 6.6 Hz, 
6H) ; 
13
C NMR  (75 MHz, CD3OD) : δ = 177.3, 175.8, 174.4, 173.3, 171.6, 157.8, 155.7, 133.5, 
130.5, 126.9, 124.4, 121.0, 113.5, 104.4 (C1Hα), 100.3 (C1Hβ), 8.7, 77.9, 76.7, 75.1, 73.5, 72.6, 
71.6, 71.5, 71.1, 68.6, 67.2, 60.1, 57.0, 53.0, 51.7, 45.8, 40.5, 37.9, 37.7, 37.4, 32.5, 32.2, 30.2, 
28.7, 28.1, 26.9, 23.7, 22.1, 19.7, 19.3, 18.6, 17.9; HRMS (TOF, ESI, ion polarity positive, H2O/ 
MeOH): m/z [M+H]
+
, calcd for C41H69N8O15 913.4882; found 913.4883, m/z [M+Na]
+
, calcd for 
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 methyl-butanamide (22). Same procedure as described for 16a from 18 (38 mg, 0.033 mmol) in 
dry CH₂Cl₂ (270 µL) to yield 22 as a white solid (40 mg, quantitative, α/β 50/50). Rf = 0 
(CH₂Cl₂/ CH₃OH: 95/5); ¹H NMR (300 MHz, CD3OD) : δ = 8.12 (m, 1H); 7.77 (d, J = 8.9 Hz, 
1H); 7.35-7.26 (m, 15H); 7.10 (d, J = 8.9 Hz, 1H); 5.07-4.61 (m, 6.50H, 6H+H1β); 4.44 (d, J = 
7.9 Hz, 0.50H, H1α); 4.40 (m, 1H); 4.17 (m, 1H); 4.02 (m, 1H); 3.94 (s, 3H); 3.86-3.35 (m, 12H); 
2.56 (m, 2H); 2.34-1.98 (m, 5H); 1.84 (m, 2H); 1.51-1.47 (m, 3H); 1.30 (s, 3H); 0.99 (m, 12H) ; 
13
C NMR  (75 MHz, CD3OD) : δ = 174.1, 173.0, 171.0, 171.5, 171.0  165.4, 155.6, 140.2, 140.0, 
139.9, 139.7, 139.5, 133.5, 129.4-128.5, 126.8, 124.3 , 121.0, 113.4, 104.8 (C1Hα), 98.0 (C1Hβ), 
85.7, 83.2, 83.0, 81.4, 79.0, 76.4, 76.0, 75.9, 75.6, 73.9, 71.7 70.6, 68.5, 68.3, 68.2,  67.3, 60.7, 
58.8, 56.9, 50.3, 49.9, 38.0, 37.6, 37.5, 32.0, 31,9, 30.4, 30.4, 23.6, 19.8, 19.0, 18.9, 18.7, 17.8 ; 
HRMS (TOF, ESI, ion polarity positive, H2O/MeOH): m/z [M+H]
+
, calcd for C56H76N7O13 
1054.5501; found 1054.5524, m/z [M+Na]
+
, calcd for C56H75N7O13Na 1076.5321; found 




Same procedure as described for 16a from 19 (38 mg, 0.029 mmol) in dry CH₂Cl₂ (220 µL), to 
afford 23 as a white solid (35.5 mg, quantitative, α/β 50/50). Rf = 0 (CH₂Cl₂/ CH₃OH  : 95/5); ¹H 
NMR (300 MHz, CDCl3) : δ = 11.10 (sl, 1H) ; 10.65 (m, 1H); 9.52 (m, 1H); 8.50-8.01 (m, 7H); 
7.32- 7.25 (m, 21H,); 6.84 (m, 1H); 5.25-4.49 (m, 11.50H, 11H+H1β); 4.36 (m, 1.50H, 1H+H1α); 
3.87 (s, 3H);  3.78 – 2.93 (m, 16H); 2.51 (s, 2H); 2.11 (s, 3H); 1.96- 1.81 (m, 5H); 1.50 (s, 3H); 
1.44 (m, 4H); 0.88-0.85 (m, 6H) ; 
13
C NMR  (75 MHz, CDCl3) : δ =  173.2, 172.0, 171.5, 171.3, 
169.9, 165.5, 158.8, 153.6, 138.6, 138.2, 138.6, 138.0, 136.6, 136.5, 135.9, 133.0, 128.4, 
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 128.3,127.9, 127.8, 127.7, 127.6, 125.8, 122.9, 117.6, 111.9, 103.9 (C1Hα), 97.1 (C1Hβ), 84.4, 
82.1, 81.8, 80.0, 78.2, 77.5, 75.5, 74.9, 74.7, 74.6, 72.9, 69.6, 67.6, 66.5, 59.3, 59.1, 56.3 , 51.3, 
50.0, 49.6, 40.5, 36.7, 36.5, 36.2, 32.6, 31.4,  29.2, 23.9, 22.4, 19.0, 18.4, 17.3 ; HRMS (TOF, 
ESI, ion polarity positive, H2O/ MeOH): m/z [M+H]
+
, calcd for C65H85N8O15 1217.6134; found 
1217.6168, m/z [M+Na]
+
, calcd for C65H84N8O15Na  1239.5954; found 1239.5972, HPLC purity: 
TR (α,β) = 19.24, 19.67 min., 91.1 %. 
Fluorescence-detected Thioflavin-T binding assay 
Thioflavin T was obtained from Sigma. Aβ1-42 was purchased from American Peptide. The 
peptide was dissolved in an aqueous 1% ammonia solution to a concentration of 1 mM and then, 
just prior to use, was diluted to 0.2 mM with 10 mM Tris-HCl, 100 mM NaCl buffer (pH 7.4). 
Stock solutions of glycopeptides were dissolved in DMSO with the final concentration kept 
constant at 0.5% (v/v). 
Thioflavin T fluorescence was measured to evaluate the development of Aβ1-42 fibrils over 
time using a fluorescence plate reader (Fluostar Optima, BMG labtech) with standard 96-well 
black microtiter plates. Experiments were started by adding the peptide (final Aβ1-42 
concentration equal to 10 µM)  into a mixture containing 40 µM Thioflavin T in 10 mM Tris-
HCl, 100 mM NaCl buffer (pH 7.4) with and without the tested compounds at different 
concentrations (100, 50, 10, 1 µM) at room temperature. The Th-T fluorescence intensity of each 
sample (performed in duplicate or triplicate) was recorded with 440/485 nm excitation/emission 
filters set for 42 hours performing a double orbital shaking of 10 s. before the first cycle. The 
fluorescence assays were performed between 2 and 4 times on different days, with the same 
batch of peptide. The ability of compounds to inhibit/accelerate Aβ1-42 aggregation was 
assessed considering both the time of the half-life of aggregation (t1/2) and the intensity of the 
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 experimental fluorescence plateau (F). The relative extension (or reduction) of t1/2 is defined as 
the experimental t1/2 in the presence of the tested compound relative to the one obtained without 
the compound and is evaluated as the following percentage: t1/2(Aβ+compound) / t1/2(Aβ) x 
100. The decrease (or increase) of the experimental plateau is defined as the intensity of 
experimental fluorescence plateau observed with the tested compound relative to the value 
obtained without the compound and is evaluated as the absolute value of following percentage : 
|FAβ - FAβ+compound| / FAβ x 100 (a decrease is indicated with a (‒) and an increase with a 
(+). 
Transmission electron microscopy 
Samples were prepared under the same conditions as in the ThT-fluorescence assay. Aliquots 
of Aβ1-42 (10 µM in 10 mM Tris-HCl, 100 mM NaCl NaCl, pH 7.4 in the presence and absence 
of the tested compounds) were adsorbed onto 300-mesh carbon grids for 2 min, washed and 
dried. The samples were negatively stained for 45 s. on 2 % uranyl acetate in water. After 
draining off the excess of staining solution and drying, images were obtained using a ZEISS 912 
Omega electron microscope operating at an accelerating voltage of 80 kV. 
Capillary electrophoresis  
Sample preparation: the commercial Aβ1-42  was dissolved upon reception in 0.16% NH4OH 
(at 2 mg/mL) for 10 minutes at 20°C, followed by an immediate lyophilization. The dried sample 
was then stored at -20°C until use.  
CE experiments were carried out with a P/ACE TM MDQ Capillary Electrophoresis System 
(Beckman Coulter Inc., Brea, CA, USA) equipped with a photodiode array detector. UV 
Detection was performed at 190 nm. The sample (as previously described) was reconstituted by 
dissolution in 20 mM phosphate buffer pH 7.4 containing DMSO (control or stock solutions of 
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 glycopeptidomimetic dissolved in DMSO). A constant DMSO/phosphate buffer ratio at 2.5% 
(v/v) was used for each sample. The final peptide concentration was set at 100 µM regardless the 
peptide/compound ratio. 
For the CE separation of Aβ oligomers, fused silica capillary 60 cm (10.2 cm to the detector) 
50 µm I.D. were used. The background electrolyte was a 80 mM phosphate buffer, pH 7.4. The 
separation was carried out under -20 kV at 25°C. The sample was injected from the outlet by 
hydrodynamic injection at 0.5 psi for 10 s. After each run, the capillary was rinsed for 3.5 min 
with NaOH 1 M, 3.5 min with water, 1 min with DMSO 10 %, 1 min with SDS 50 mM, and 
equilibrated with running buffer for 3 min.  
NMR spectroscopy 







N TCI cryoprobe with Z-axis gradient. NMR spectra were processed and 
analysed with TopSpin software (Bruker).  
The conformation of 3β was studied in aqueous solution, either in H2O/D2O (90/10 v/v) or in 




C resonances were assigned 
using 1D 
1













C HSQC, and 2D 1H-
13





C chemical shifts were calibrated using DSS (sodium 4,4-dimethyl-4-silapentane-1-




C resonance assignments of 3β are listed in 
Tables S1 and S2. Vicinal coupling constants were extracted from 1D 
1
H WATERGATE. The 
temperature gradients of the amide proton chemical shifts were derived from 1D 
1
H 
WATERGATE spectra recorded between 5 °C and 30 °C. 
Page 44 of 58
ACS Paragon Plus Environment





























































 Samples of Aβ1-42 in the absence or in the presence of 3β were prepared in Shigemi tubes (280 
µL volume) in 50 mM sodium phosphate, pH 7.4 containing 10% D2O. Synthetic Aβ1-42 peptide 





labelled recombinant Aβ1-42. Solid phase peptide synthesis of Aβ1-42 was   performed at the 
Institut de Biologie Intégrative (IFR83- Université Pierre et Marie Curie). Recombinant Aβ1-42 
was obtained according to the protocol of Walsh et al.35 NMR experiments were acquired at 
5 °C. 2D NOESY experiments were recorded with a mixing time of 0.2 s. 1D 
1
H STD 
experiments were acquired using a cascade of Gaussian shaped pulses (50 ms pulse, B1 field of 
0.1 kHz, total duration of 3 s) applied on resonance (–0.7 ppm) and off resonance (+30 ppm), 
alternatively. The number of scans was set to 320, corresponding to an experiment duration of 50 
min. 1D 
1
H WaterLOGSY (water-ligand observed via gradient spectroscopy) experiments were 
recorded using a Gaussian pulse of 20 ms duration for selective inversion of water magnetization 
and a mixing period of 0.5 s. The recycling delay was set to 2 s and the total number of scans 
was 1200, corresponding to an experimental time of 1 hour.  
SPR experiments 
For these studies we used the Biacore T100 (GE Healthcare, France) apparatus, which has 4 
parallel flow channels. Aβ1-42 peptide was immobilized on the carboxy-terminated dextran matrix 
on gold surface sensor chip (CM5 sensor chip, GE Healthcare, France) by an optimized amine 
coupling method. Briefly, the surface was treated with a mixture of 0.4 M EDC and 0.1 M NHS 
(1/1) in water for 7 min. at 10 µL/min. Then, a freshly prepared Aβ1-42 solution (0.05 µM) in a 10 
mM sodium acetate buffer (pH 4.6) was injected 4 times during 15 min. each at 10 µL/min on 
the NHS-activated surface. Then, a final injection of ethanolamine was done to block the non-
linked activated amine. A reference surface was prepared using the same immobilization 
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 procedure but with an ethanolamine injection instead of the peptide (blank surface). At that point 
of the process, the fixation lead to a SPR signal of 3000 RU. A rinsing step using an aqueous 
solution of NH4OH.H2O 0.1 % (9 injections of 1 min. each at 30 µL/min.) was performed in 
order to remove from the surface all the Aβ1-42 aggregates that may have been formed during the 
immobilization step. After these rinsing steps, the chip gave a signal of about 1500 RU. 
Binding of compounds 3β, 1 and curcumin to Aβ1-42 fixed on the SPR chips : Solutions of 
compounds in 150 mM PBS containing 2% DMSO solubilized in DMSO were injected on the 
Aβ1-42 surface for 1 min. at 80 µL/min. The rinsing step was performed using the running buffer 
for 5 min. and the regeneration step using the aqueous solution of NH4OH.H2O 0.1 % (3 times 
for 5 min at 30 µL/min.). The range of concentrations started from 12.5 µM and ended at 200 
µM in PBS (150 mM), 2% DMSO. A DMSO solvent correction was applied to the raw signals 
and non-specific signal was subtracted using the blank channel. 
Cell toxicity 
SH-SY5Y neuroblastoma cells were grown in low serum Optimem (Life Technologies) for 24 
hours at 37˚C, 5% CO2 in a 96 well plate at 20 000 cells per well. Aβ1-42 was dissolved in sterile 
PBS at 50 µM concentration in the presence of 1, 5, 10 and 50 µM of either 1 or 3 for 24 hours at 
room temperature, along with a control incubation with no inhibitor. After the 24 hour period, 
media was removed from the cells and replaced with Optimem containing the pre-incubated Aβ1-
42 plus inhibitor diluted one in ten (5 µM Aβ final concentration) in quadruplicate.  The cells 
were incubated for a further 24 hours as before and the cell viability (MTS assay) and cell 
proliferation (LDH assay) assessed using the CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay (Promega) and CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega) respectively. The assays were repeated twice and representative samples are shown. 
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 Plasma stability 
Both 1 and 3 were dissolved at 40 µM in DMSO and then diluted to 1 µM in 10% human 
plasma, 90% sterile PBS.  One hundred microlitre samples were run on an HPLC system 
(Dionex, with C18 Jupiter column from Phenomenex) using a gradient of 0-80%B (Buffer A: 
0.1% trifluoroacetic acid in water, Buffer B: 0.05% trifluoroacetic acid in acetonitrile). Samples 
were monitored at 230 nm. After 24 hour incubation at 37˚C 100 µL samples were run on the 
same gradient and monitored as before. 
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